abstract |
The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: n n n n n n n n n n which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer. |